Poster

A SMART Platform For Scalable Biotherapeutic Development: cDNA To 200L Single Use Stirred Tank Bioreactor

Source: Pall

Establishing a platform for developing and manufacturing therapeutic proteins will eliminate the bottleneck between cell line development and tech transfer. The Celltheon SMARTTM Technology Platform in combination with Pall Biotech’s manufacturing equipment accelerates time from cDNA to pilot scale with a pre-defined fed-batch and downstream processing platform for monoclonal antibodies and difficult to express therapeutic proteins In this case study, Celltheon demonstrates a workflow established to develop an RCB followed by scale-up and reproducible product quality from bench to pilot scale in the 200 L Allegro STR single-use bioreactor.

VIEW THE POSTER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: